Insmed to Present at Goldman Sachs Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: PRnewswire
- Conference Announcement: Insmed will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on June 9, 2026, at 10:00 a.m. ET, which is expected to attract investor and industry attention, further enhancing the company's visibility in the biopharmaceutical sector.
- Live Webcast: The event will be webcast live, accessible via the investor relations section of the company's website, and will be archived for 30 days post-event, ensuring that investors who cannot attend live can still access important information, thereby enhancing transparency.
- Company Overview: Insmed is a people-first global biopharmaceutical company focused on delivering first- and best-in-class therapies, particularly in the area of chronic lung diseases with two approved therapies, showcasing its competitive edge and innovative capabilities in the industry.
- Technological Innovation: The company is advancing a diverse portfolio of technologies and treatment modalities, including gene therapy and AI-driven protein engineering, indicating Insmed's leading position in biopharmaceuticals and its strong commitment to addressing patient needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 108.370
Low
162.00
Averages
219.50
High
263.00
Current: 108.370
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insmed to Present at Goldman Sachs Healthcare Conference
- Conference Announcement: Insmed will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on June 9, 2026, at 10:00 a.m. ET, which is expected to attract investor and industry attention, further enhancing the company's visibility in the biopharmaceutical sector.
- Live Webcast: The event will be webcast live, accessible via the investor relations section of the company's website, and will be archived for 30 days post-event, ensuring that investors who cannot attend live can still access important information, thereby enhancing transparency.
- Company Overview: Insmed is a people-first global biopharmaceutical company focused on delivering first- and best-in-class therapies, particularly in the area of chronic lung diseases with two approved therapies, showcasing its competitive edge and innovative capabilities in the industry.
- Technological Innovation: The company is advancing a diverse portfolio of technologies and treatment modalities, including gene therapy and AI-driven protein engineering, indicating Insmed's leading position in biopharmaceuticals and its strong commitment to addressing patient needs.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Insmed Q1 2026 Earnings Call Highlights
- Strong Growth for BRINSUPRI: Insmed reported a 44% sequential growth for BRINSUPRI in Q1 2026, with management expressing confidence in achieving at least $1 billion in revenue guidance for the year, indicating sustained product demand.
- Positive ARIKAYCE Data: The ENCORE study for ARIKAYCE demonstrated that early treatment can convert over 80% of patients to negative sputum cultures, with expectations for expanded labeling in the first half of 2027, presenting a peak sales opportunity exceeding $1 billion.
- Healthy Cash Flow Position: As of the end of Q1 2026, Insmed had approximately $1.2 billion in cash and cash equivalents, with expectations to achieve sustainable cash flow positivity by 2027, enhancing the company's financial stability for future operations.
- International Market Challenges: Management noted that the international pricing policy (MFN) has caused a pause in BRINSUPRI's launch efforts in Europe and the U.K., highlighting the significant impact of external policies on the company's strategic execution.
See More
U.S. Stock Market Retreats as Oil Prices Surge
- Market Retreat: The S&P 500 Index fell by 0.40%, the Dow Jones Industrial Average by 0.51%, and the Nasdaq 100 by 0.28%, indicating a retreat in market sentiment as rising oil prices weigh on investor confidence and raise concerns about future economic prospects.
- Strong Employment Data: Initial jobless claims in the U.S. rose by 10,000 to 200,000, indicating a stronger labor market than the expected 205,000, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, showcasing economic resilience.
- Productivity and Costs: U.S. Q1 nonfarm productivity increased by 0.8%, surpassing expectations of 0.6%, while unit labor costs rose by 2.3%, below the anticipated 2.5%, which may influence future inflation expectations and Fed policy decisions.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at “mildly restrictive” levels, suggesting that if inflation trends worsen significantly, a reassessment of policy would be necessary, with markets pricing in only a 6% chance of a rate cut at the next FOMC meeting.
See More
US Stocks Show Mixed Movement, Tech Stocks Surge
- Tech Stock Surge: Datadog reported Q1 revenue of $1.01 billion, exceeding the consensus of $957.8 million, leading to a stock price increase of over 30%, which boosts overall market sentiment and reflects strong recovery in the tech sector amid high investor expectations for artificial intelligence.
- Stable Labor Market: Initial jobless claims rose by 10,000 to 200,000, lower than the expected 205,000, indicating resilience in the labor market, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, further enhancing market confidence.
- Crude Oil Price Decline: WTI crude oil prices fell by more than 4% as markets await updates on a potential US-Iran peace deal that could reopen the Strait of Hormuz, negatively impacting energy producers and leading to widespread declines in related stocks.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at
See More
Mixed US Stock Indices with Nasdaq 100 Reaching All-Time High
- Nasdaq Milestone: The Nasdaq 100 index rose by 0.20%, achieving a new all-time high, driven by strong performance in tech stocks, particularly Datadog, which surged over 30% following its blowout earnings report.
- Oil Price Decline: WTI crude oil prices fell by more than 4% today as the market awaits updates on a potential US-Iran peace deal that could reopen the Strait of Hormuz, impacting global oil prices and supply chains.
- Stable Labor Market: Initial US unemployment claims rose by 10,000 to 200,000, below expectations of 205,000, indicating labor market resilience, while continuing claims unexpectedly fell to a 2.25-year low of 1.766 million.
- Strong Corporate Earnings: So far, 84% of the 411 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, reflecting ongoing improvements in corporate profitability, although growth outside the tech sector is only 3%.
See More
Insmed to Present at Goldman Sachs Healthcare Conference
- Conference Announcement: Insmed will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on June 9, 2026, at 10:00 a.m. ET, which is expected to attract investor and industry attention, further enhancing the company's visibility in the biopharmaceutical sector.
- Live Webcast: The event will be webcast live, accessible via the investor relations section of the company's website, and will be archived for 30 days post-event, ensuring that investors who cannot attend live can still access important information, thereby enhancing transparency.
- Company Overview: Insmed is a people-first global biopharmaceutical company focused on delivering first- and best-in-class therapies, particularly in the area of chronic lung diseases with two approved therapies, showcasing its competitive edge and innovative capabilities in the industry.
- Technological Innovation: The company is advancing a diverse portfolio of technologies and treatment modalities, including gene therapy and AI-driven protein engineering, indicating Insmed's leading position in biopharmaceuticals and its strong commitment to addressing patient needs.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Insmed Q1 2026 Earnings Call Highlights
- Strong Growth for BRINSUPRI: Insmed reported a 44% sequential growth for BRINSUPRI in Q1 2026, with management expressing confidence in achieving at least $1 billion in revenue guidance for the year, indicating sustained product demand.
- Positive ARIKAYCE Data: The ENCORE study for ARIKAYCE demonstrated that early treatment can convert over 80% of patients to negative sputum cultures, with expectations for expanded labeling in the first half of 2027, presenting a peak sales opportunity exceeding $1 billion.
- Healthy Cash Flow Position: As of the end of Q1 2026, Insmed had approximately $1.2 billion in cash and cash equivalents, with expectations to achieve sustainable cash flow positivity by 2027, enhancing the company's financial stability for future operations.
- International Market Challenges: Management noted that the international pricing policy (MFN) has caused a pause in BRINSUPRI's launch efforts in Europe and the U.K., highlighting the significant impact of external policies on the company's strategic execution.
See More
U.S. Stock Market Retreats as Oil Prices Surge
- Market Retreat: The S&P 500 Index fell by 0.40%, the Dow Jones Industrial Average by 0.51%, and the Nasdaq 100 by 0.28%, indicating a retreat in market sentiment as rising oil prices weigh on investor confidence and raise concerns about future economic prospects.
- Strong Employment Data: Initial jobless claims in the U.S. rose by 10,000 to 200,000, indicating a stronger labor market than the expected 205,000, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, showcasing economic resilience.
- Productivity and Costs: U.S. Q1 nonfarm productivity increased by 0.8%, surpassing expectations of 0.6%, while unit labor costs rose by 2.3%, below the anticipated 2.5%, which may influence future inflation expectations and Fed policy decisions.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at “mildly restrictive” levels, suggesting that if inflation trends worsen significantly, a reassessment of policy would be necessary, with markets pricing in only a 6% chance of a rate cut at the next FOMC meeting.
See More
US Stocks Show Mixed Movement, Tech Stocks Surge
- Tech Stock Surge: Datadog reported Q1 revenue of $1.01 billion, exceeding the consensus of $957.8 million, leading to a stock price increase of over 30%, which boosts overall market sentiment and reflects strong recovery in the tech sector amid high investor expectations for artificial intelligence.
- Stable Labor Market: Initial jobless claims rose by 10,000 to 200,000, lower than the expected 205,000, indicating resilience in the labor market, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, further enhancing market confidence.
- Crude Oil Price Decline: WTI crude oil prices fell by more than 4% as markets await updates on a potential US-Iran peace deal that could reopen the Strait of Hormuz, negatively impacting energy producers and leading to widespread declines in related stocks.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at
See More
Mixed US Stock Indices with Nasdaq 100 Reaching All-Time High
- Nasdaq Milestone: The Nasdaq 100 index rose by 0.20%, achieving a new all-time high, driven by strong performance in tech stocks, particularly Datadog, which surged over 30% following its blowout earnings report.
- Oil Price Decline: WTI crude oil prices fell by more than 4% today as the market awaits updates on a potential US-Iran peace deal that could reopen the Strait of Hormuz, impacting global oil prices and supply chains.
- Stable Labor Market: Initial US unemployment claims rose by 10,000 to 200,000, below expectations of 205,000, indicating labor market resilience, while continuing claims unexpectedly fell to a 2.25-year low of 1.766 million.
- Strong Corporate Earnings: So far, 84% of the 411 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, reflecting ongoing improvements in corporate profitability, although growth outside the tech sector is only 3%.
See More
